Biogen (BIIB) Revenue (2009 - 2026)

Biogen (BIIB) has reported Revenue for 18 consecutive years, with $2.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Revenue rose 1.93% year-over-year to $2.5 billion; the TTM figure through Mar 2026 stood at $9.9 billion (up 1.23% YoY), while the FY2025 annual figure was $9.9 billion, up 2.22% from the prior year.
• Revenue came in at $2.5 billion for Q1 2026 at Biogen, up from $2.3 billion in the prior quarter.
• The five-year high for Revenue was $2.6 billion in Q2 2025, with the low at $2.3 billion in Q4 2025.
• Average Revenue over 5 years is $2.5 billion, with a median of $2.5 billion recorded in 2024.
• Across the five-year window, Revenue fell 9.73% in 2022 and gained 7.33% in 2025, its largest moves.
• Year by year, Revenue stood at $2.5 billion in 2022, then slipped by 6.2% to $2.4 billion in 2023, then grew by 2.87% to $2.5 billion in 2024, then declined by 7.14% to $2.3 billion in 2025, then climbed by 8.7% to $2.5 billion in 2026.
• According to Business Quant data, Revenue over the past three periods registered $2.5 billion, $2.3 billion, and $2.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.